Description of the medicine: Filgrastim (Filgrastim)
Synonyms: Neupogen, Neupogen, Neupogen.
A polypeptide (non-glycolized) containing 175 amino acid residues. The molecular weight is 8800 daltons. (C 845 H 1330 N 223 O 243 S 9 ).
Obtained by genetic engineering through Escherichia coli. Contains the gene for granulocyte colony stimulating factor in humans.
Stimulates granulocytopoiesis. Interacting with receptors on the surface of hematopoietic cells, accelerates the biosynthesis and release of neutrophils in the bone marrow.
Apply intravenously and subcutaneously.
Doses are set individually depending on the indications, the severity of the process and the patient's sensitivity to the drug.
Treatment begins no earlier than 24 hours after the end of chemotherapy. For cytotoxic neutropenia, 500,000 units / kg per day are administered, for bone marrow transplantation - 1,000,000 units / kg per day, for severe chronic and congenital neutropenia, the initial dose is 1,200,000 units / kg per day. Treatment is continued until the normal neutrophil content in the blood (usually about 2 weeks).
Side effects are rare. However, pain in the bones and muscles, redness of the skin and pain at the injection site, and allergic reactions are possible.
Release form: solution for injection in a syringe tube of 0.5; 1 and 1.6 ml (30,000,000 and 48,000,000 units) and in 1 ml vials (30,000,000 units) and 1.6 ml (48,000,000 units).
For infusion, the contents of the vial are diluted in a 5% glucose solution.